Pulse Biosciences (NASDAQ:PLSE) Price Target Raised to $43.00

Pulse Biosciences (NASDAQ:PLSE) had its price objective lifted by stock analysts at Canaccord Genuity Group from $32.00 to $43.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 1.39% from the stock’s current price.

PLSE has been the topic of several other reports. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Pulse Biosciences Stock Performance

NASDAQ PLSE opened at $42.41 on Monday. The firm’s fifty day simple moving average is $29.01 and its two-hundred day simple moving average is $23.71. The firm has a market capitalization of $2.94 billion, a P/E ratio of -35.94 and a beta of 1.61. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $45.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 100.22%. As a group, sell-side analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PLSE. Russell Investments Group Ltd. lifted its position in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Pulse Biosciences by 6.7% during the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after buying an additional 1,300 shares in the last quarter. Westside Investment Management Inc. increased its holdings in Pulse Biosciences by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after buying an additional 1,886 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.